Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Evaluation of Tonabersat for DME
NCT05727891 · View on ClinicalTrials.gov ↗
Study Summary
This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Tonabersat
Study Locations (20)
California
- Retina Associates of Southern California — Huntington Beach
- Loma Linda University — Loma Linda
- East Bay Retina Consultants, Inc. — Oakland
- Southern California Desert Retina Consultants, Inc. — Palm Desert
- Macula Retina Vitreous Institute — Torrance
Florida
- National Ophthalmic Research Institute — Fort Myers
- University of Florida- Jacksonville — Jacksonville
- Central Florida Retina Institute — Lakeland
- Florida Retina Consultants — Lakeland
- Southeast Eye Institute, P.A. dba Eye Associates of Pinellas — Pinellas Park
Georgia
- Southeast Retina Center — Augusta
- Thomas Eye Group — Sandy Springs
Massachusetts
- Boston Medical Center Corporation — Boston
- Joslin Diabetes Center — Boston
Illinois
- Illinois Retina Associates — Oak Park
Indiana
- Midwest Eye Institute — Indianapolis
Louisiana
- Joseph E. Humble and Raymond Haik PTRS DBA Eye Assoc of Northeast Louisiana — West Monroe
Maryland
- Elman Retina Group — Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2026-01 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05727891
The ClinicalTrials.gov registry entry for NCT05727891 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jaeb Center for Health Research, which has 134 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05727891 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05727891 about?
NCT05727891 is a clinical study titled "Evaluation of Tonabersat for DME". This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
What is the current status of trial NCT05727891?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2023-05-02. Estimated completion is 2026-01.
What conditions does trial NCT05727891 study?
This clinical trial studies the following conditions: Diabetic Macular Edema. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05727891?
The interventions under investigation include: Placebo (OTHER), Tonabersat (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05727891?
This trial is sponsored by Jaeb Center for Health Research, which has 134 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05727891 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.